Amylyx Pharmaceuticals Inc Asset Resilience Ratio
Amylyx Pharmaceuticals Inc asset resilience ratio. Amylyx Pharmaceuticals Inc (AMLX) has an Asset Resilience Ratio of 76.14% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See AMLX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Amylyx Pharmaceuticals Inc (2020–2025)
Asset resilience ratio of Amylyx Pharmaceuticals Inc from 2020 to 2025. This chart shows how Amylyx Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Amylyx Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Amylyx Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Amylyx Pharmaceuticals Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $201.43 Million | 76.14% |
| Total Liquid Assets | $201.43 Million | 76.14% |
Asset Resilience Insights
- Very High Liquidity: Amylyx Pharmaceuticals Inc maintains exceptional liquid asset reserves at 76.14% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Amylyx Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Amylyx Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Amylyx Pharmaceuticals Inc Asset Resilience Ratio by Year (2020–2025)
Amylyx Pharmaceuticals Inc asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Amylyx Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 27.15% | $90.33 Million | $332.64 Million | -24.03pp |
| 2024-12-31 | 51.18% | $99.11 Million | $193.63 Million | +12.31pp |
| 2023-12-31 | 38.88% | $201.16 Million | $517.45 Million | -33.78pp |
| 2022-12-31 | 72.66% | $284.42 Million | $391.45 Million | +29.17pp |
| 2021-12-31 | 43.49% | $45.93 Million | $105.61 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $14.10 Million | -- |
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and… Read more